Cited by 377Protein Degradation and InhibitorsUbiquitin and proteasome pathwaysChemical Synthesis and Analysis

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs

Open access

An, Sainan, Fu, Liwu·2018·EBioMedicine

DOI 10.1016/j.ebiom.2018.09.005PMC PMC6197674

Open this paper in CoChat — free account

Abstract

There are several challenges towards the development and clinical use of small molecule inhibitors, which are currently the main type of targeted therapies towards intracellular proteins. PROteolysis-TArgeting Chimeras (PROTACs) exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins. Recently, small-molecule PROTACs with high potency have been frequently reported. In this review, we summarize the emerging characteristics of small-molecule PROTACs, such as inducing a rapid, profound and sustained degradation, inducing a robust inhibition of downstream signals, displaying enhanced target selectivity, and overcoming resistance to small molecule inhibitors. In tumor xenografts, small-molecule PROTACs can significantly attenuate tumor progression. In addition, we also introduce recent developments of the PROTAC technology such as homo-PROTACs. The outstanding advantages over traditional small-molecule drugs and the promising preclinical data suggest that small-molecule PROTAC technology has the potential to greatly promote the development of targeted therapy drugs.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ebiom.2018.09.005

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein
Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Structural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
The dTAG system for immediate and target-specific protein degradation
Nabet, B., Roberts, J. M., Buckley, D. L., Paulk, J., Dastjerdi, S., Yang, A., Leggett, A. L., Erb, M. A., Lawlor, M. A., Souza, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0021-8 · Cited by 1,118
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065

Flagged first, then by citations

Show all 75 references

Research works printed but not linked: 1

Lavanya, 2014, Small molecule inhibitors as emerging cancer therapeutics, Integr Cancer Sci Ther, 1

Sorted by citations

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W. M., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,813
Exploring the next generation of antibody–drug conjugates
Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00850-2 · Cited by 659
PROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y.-G., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 663
PROTACs: An Emerging Therapeutic Modality in Precision Medicine
Nalawansha, D. A., & Crews, C. M. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.07.020 · Cited by 523
Challenges and Opportunities in Cancer Drug Resistance
Ward, R. A., Fawell, S. E., Floc’h, N., Flemington, V., McKerrecher, D., & Smith, P. D. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00383 · Cited by 461
Proteolysis targeting chimeras (PROTACs) in ‘beyond rule-of-five’ chemical space: Recent progress and future challenges
Edmondson, S. D., Yang, B., & Fallan, C. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.04.030 · Cited by 422
An overview of PROTACs: a promising drug discovery paradigm
Zi, L., Hu, M., Yu, Y., Du, C., Zhou, H., Liu, C., Chen, Y., Fan, L., Ma, H., Gong, Y., et al. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00112-0 · Cited by 380
Degradation of proteins by PROTACs and other strategies
Wang, Y., Jiang, X., Feng, F., Liu, W., & Sun, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.001 · Cited by 335
The PROTAC technology in drug development
Zou, Y., Ma, D., & Wang, Y. (2019) · Cell Biochemistry and Function · doi:10.1002/cbf.3369 · Cited by 312
The PROTACtable genome
Schneider, M., Radoux, C. J., Hercules, A., Ochoa, D., Dunham, I., Zalmas, L.-P., Hessler, G., Ruf, S., Shanmugasundaram, V., Hann, M. M., et al. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00245-x · Cited by 273
Development of dual and selective degraders of cyclin-dependent kinases 4 and 6
Jiang, B., Wang, E. S., Donovan, K. A., Liang, Y., Fischer, E. S., Zhang, T., & Gray, N. S. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201901336 · Cited by 272
E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points
Bricelj, A., Steinebach, C., Kuchta, R. D., Gütschow, M., & Sosič, I. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.707317 · Cited by 232
Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands
Han, X., Zhao, L., Xiang, W., Qin, C., Miao, B., Xu, T., Wang, M., Yang, C., Chinnaswamy, K., Stuckey, J. A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01393 · Cited by 225
The role of ubiquitination and deubiquitination in tumor invasion and metastasis
Han, S., Wang, R., Zhang, Y., Li, X., Gan, Y., Gao, F., Rong, P., Wang, W., & Li, W. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.69411 · Cited by 223
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)
Sánchez-Martínez, C., Lallena, M. J., Sanfeliciano, S. G., & de Dios, A. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126637 · Cited by 204
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Wang, C., Zhang, Y., Chen, W., Wu, Y., & Xing, D. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02024-9 · Cited by 222
Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader
Potjewyd, F., Turner, A. W., Beri, J., Rectenwald, J. M., Norris-Drouin, J. L., Cholensky, S. H., Margolis, D. M., Pearce, K. H., Herring, L. E., & James, L. I. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.11.006 · Cited by 181
Emerging strategies to overcome resistance to third-generation EGFR inhibitors
Shi, K., Wang, G., Pei, J., Zhang, J., Wang, J., Ouyang, L., Wang, Y., & Li, W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01311-6 · Cited by 174
Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer
Han, X., Zhao, L., Xiang, W., Qin, C., Miao, B., McEachern, D., Wang, Y., Metwally, H., Wang, L., Matvekas, A., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00882 · Cited by 170
PROTACs– a game-changing technology
Konstantinidou, M., Li, J., Zhang, B., Wang, Z., Shaabani, S., ter Brake, F., Essa, K., & Dömling, A. S. S. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1659242 · Cited by 171
Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs
Girardini, M., Maniaci, C., Hughes, S. J., Testa, A., & Ciulli, A. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.02.048 · Cited by 163
The role of reversible and irreversible covalent chemistry in targeted protein degradation
Kiely‐Collins, H., Winter, G. E., & Bernardes, G. J. L. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.03.005 · Cited by 160
Developments of CRBN-based PROTACs as potential therapeutic agents
Wang, C., Zhang, Y., Wu, Y., & Xing, D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113749 · Cited by 158
Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity
Klein, V. G., Bond, A. G., Craigon, C., Lokey, R. S., & Ciulli, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01496 · Cited by 152
Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments
Jung, Y. J., Tweedie, D., Scerba, M. T., & Greig, N. H. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00313 · Cited by 156
Intracellular Delivery of Glutathione Peroxidase Degrader Induces Ferroptosis In Vivo
Luo, T., Zheng, Q., Shao, L., Ma, T., Mao, L., & Wang, M. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202206277 · Cited by 136
Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling
You, I., Erickson, E. C., Donovan, K. A., Eleuteri, N. A., Fischer, E. S., Gray, N. S., & Toker, A. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.11.014 · Cited by 131
HECT E3 ubiquitin ligases – emerging insights into their biological roles and disease relevance
Wang, Y., Argiles-Castillo, D., Kane, E. I., Zhou, A., & Spratt, D. E. (2020) · Journal of Cell Science · doi:10.1242/jcs.228072 · Cited by 128
Bivalent Ligands for Protein Degradation in Drug Discovery
Scheepstra, M., Hekking, K. F. W., Hijfte, L. V., & Folmer, R. H. A. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.01.006 · Cited by 125
Strategies for designing proteolysis targeting chimaeras (PROTACs)
He, S., Dong, G., Cheng, J., Wu, Y., & Sheng, C. (2022) · Medicinal Research Reviews · doi:10.1002/med.21877 · Cited by 120
Novel CRBN-Recruiting Proteolysis-Targeting Chimeras as Degraders of Stimulator of Interferon Genes with In Vivo Anti-Inflammatory Efficacy
Liu, J., Yuan, L., Ruan, Y., Deng, B., Yang, Z., Ren, Y., Li, L., Liu, T., Zhao, H., Mai, R., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01948 · Cited by 120
A bibliometric analysis of PROTAC from 2001 to 2021
Li, D., Yu, D., Li, Y., & Yang, R. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114838 · Cited by 125
Development of Selective Histone Deacetylase 6 (HDAC6) Degraders Recruiting Von Hippel–Lindau (VHL) E3 Ubiquitin Ligase
Yang, K., Wu, H., Zhang, Z., Leisten, E. D., Nie, X., Liu, B., Wen, Z., Zhang, J., Cunningham, M. D., & Tang, W. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00046 · Cited by 124
Quantitating Endosomal Escape of a Library of Polymers for mRNA Delivery
Jiang, Y., Qiao, L., Wang, Y., Xu, E., Ho, A. S. L., Singh, P., Wang, Y., Jiang, Z., Yang, F., Tietjen, G. T., et al. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b04426 · Cited by 111
Development of BromoTag: A “Bump-and-Hole”–PROTAC System to Induce Potent, Rapid, and Selective Degradation of Tagged Target Proteins
Bond, A. G., Craigon, C., Chan, K.-H., Testa, A., Karapetsas, A., Fasimoye, R. Y., Macartney, T., Blow, J. J., Alessi, D. R., & Ciulli, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01532 · Cited by 116
Targeted protein degradation directly engaging lysosomes or proteasomes
Kim, J., Byun, I., Kim, D. Y., Joh, H., Kim, H. J., & Lee, M. J. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00344b · Cited by 108
Discovery of potent small molecule PROTACs targeting mutant EGFR
Zhao, H., Yang, X., Lei, H., Xi, X.-X., Lu, S., Zhang, J., Xin, M., & Zhang, S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112781 · Cited by 107
Discovery of a potent SCAP degrader that ameliorates HFD-induced obesity, hyperlipidemia and insulin resistance via an autophagy-independent lysosomal pathway
Zheng, Z., Zhu, S.-T., Cheng, H., Zhang, X., Cheng, G., Thu, P. M., Wang, S. P., Li, H., Ding, M., Qiang, L., et al. (2020) · Autophagy · doi:10.1080/15548627.2020.1757955 · Cited by 102
Bifunctional chemical probes inducing protein–protein interactions
Maniaci, C., & Ciulli, A. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.07.003 · Cited by 100
Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance
Lin, X., Xiang, H., & Luo, G. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112689 · Cited by 104
Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins
Lin, J., Jin, J., Shen, Y., Zhang, L., Gong, G., Bian, H., Chen, H., Nagle, D. G., Wu, Y., Zhang, W., et al. (2021) · Theranostics · doi:10.7150/thno.62686 · Cited by 102
Novel immunomodulatory drugs and neo-substrates
Gao, S., Wang, S., & Song, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-0182-y · Cited by 95
Protein degradation technology: a strategic paradigm shift in drug discovery
Li, H., Dong, J., Cai, M., Xu, Z., Cheng, X., & Qin, J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01146-7 · Cited by 96
Identification of a potent and selective covalent Pin1 inhibitor
Pinch, B. J., Doctor, Z. M., Nabet, B., Browne, C. M., Seo, H., Mohardt, M. L., Kozono, S., Lian, X., Manz, T. D., Chun, Y., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0550-9 · Cited by 90
Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer
Cimas, F. J., Niza, E., Juan, A., Noblejas‐López, M. D. M., Bravo, I., Lara‐Sánchez, A., Alonso‐Moreno, C., & Ocaña, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100986 · Cited by 90
An overview of kinase downregulators and recent advances in discovery approaches
Wang, B., Wu, H., Hu, C., Wang, H., Liu, J., Wang, W., & Liu, Q. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00826-7 · Cited by 93
Proteolysis targeting chimeras (PROTACs) in cancer therapy
Ocaña, A., & Pandiella, A. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01672-1 · Cited by 89
Structural Insights into PROTAC-Mediated Degradation of Bcl-xL
Chung, C., Dai, H., Fernández, E., Tinworth, C. P., Churcher, I., Cryan, J., Denyer, J. C., Harling, J. D., Konopacka, A., Queisser, M. A., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00266 · Cited by 86
Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors
LaPlante, G., & Zhang, W. (2021) · Cancers · doi:10.3390/cancers13123079 · Cited by 88
Salt-inducible kinase inhibition suppresses acute myeloid leukemia progression in vivo
Tarumoto, Y., Lin, S., Wang, J., Milazzo, J. P., Xu, Y., Lu, B., Yang, Z., Wei, Y., Polyanskaya, S. A., Wunderlich, M., et al. (2019) · Blood · doi:10.1182/blood.2019001576 · Cited by 77
PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein Degradation
Syahputra, E. W., Lee, H., Cho, H., Park, H. J., Park, K.-S., & Hwang, D. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17040501 · Cited by 88
Multiple Myeloma Therapy: Emerging Trends and Challenges
Dima, D., Jiang, D., Singh, D. J., Hasipek, M., Shah, H., Ullah, F., Khouri, J., Maciejewski, J. P., & Jha, B. K. (2022) · Cancers · doi:10.3390/cancers14174082 · Cited by 92
Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs)
Saraswat, A. L., Vartak, R., Hegazy, R. R., Patel, A., & Patel, K. R. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103387 · Cited by 83
Autophagy in the cancer-immunity dialogue
Yamazaki, T., Pedro, J. M. B., Galluzzi, L., Kroemer, G., & Pietrocola, F. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.003 · Cited by 80
HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations
Du, Y., Chen, Y., Wang, Y., Chen, J., Lu, X., Zhang, L., Li, Y., Wang, Z., Ye, G., & Zhang, G. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0835 · Cited by 83
Recent Advances in PROTACs for Drug Targeted Protein Research
Yao, T., Xiao, H., Wang, H., & Xu, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810328 · Cited by 79
PIKES Analysis Reveals Response to Degraders and Key Regulatory Mechanisms of the CRL4 Network
Reichermeier, K. M., Straube, R., Reitsma, J. M., Sweredoski, M. J., Rose, C. M., Moradian, A., den Besten, W., Hinkle, T., Verschueren, E., Petzold, G., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2019.12.013 · Cited by 78
Advancing targeted protein degradation for metabolic diseases therapy
Zhou, Q., Xiao, H., Yang, F., Wang, Y., Li, P., & Zheng, Z. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106627 · Cited by 77
Assays and Technologies for Developing Proteolysis Targeting Chimera Degraders
Liu, X., Zhang, X., Lv, D., Yuan, Y., Zheng, G., & Zhou, D. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0073 · Cited by 75
Targeted protein degradation in vivo with Proteolysis Targeting Chimeras: Current status and future considerations
Watt, G. F., Scott‐Stevens, P., & Gaohua, L. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.02.005 · Cited by 72
Steering the antitumor drug discovery campaign towards structurally diverse indolines
Thakur, A., Singh, A., Kaur, N., Ojha, R., & Nepali, K. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103436 · Cited by 71
Two-Stage Strategy for Development of Proteolysis Targeting Chimeras and its Application for Estrogen Receptor Degraders
Roberts, B. L., Ma, Z., Gao, A., Leisten, E. D., Yin, D., Xu, W., & Tang, W. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00140 · Cited by 73
A suite of mathematical solutions to describe ternary complex formation and their application to targeted protein degradation by heterobifunctional ligands
Han, B. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014715 · Cited by 72
The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1
Ciccone, L., Shi, C., di Lorenzo, D., Van Baelen, A.-C., & Tonali, N. (2020) · Molecules · doi:10.3390/molecules25102439 · Cited by 69
Novel approaches for the rational design of PROTAC linkers
Zagidullin, A. A., Milyukov, V. A., Rizvanov, A. A., & Bulatov, E. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00023 · Cited by 75
Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective
Zhu, Q., Chen, N., Tian, X., Zhou, Y.-L., You, Q., & Xu, X. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00172 · Cited by 70
Hydrophobic tag-based protein degradation: Development, opportunity and challenge
He, Q., Zhao, X., Wu, D., Jia, S., Liu, C., Cheng, Z., Huang, F., Chen, Y., Lu, T., & Lü, S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115741 · Cited by 71
Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs
Anderson, N. A., Cryan, J., Ahmed, A., Dai, H., McGonagle, G. A., Rozier, C., & Benowitz, A. B. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127106 · Cited by 69
A Designed Small Molecule Inhibitor of a Non-Coding RNA Sensitizes HER2 Negative Cancers to Herceptin
Costales, M. G., Hoch, D. G., Abegg, D., Childs‐Disney, J. L., Velagapudi, S. P., Adibekian, A., & Disney, M. D. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b10558 · Cited by 70
VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives
Wang, C., Zhang, Y., Wang, J., & Xing, D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113906 · Cited by 73
PROTACs: A novel strategy for cancer drug discovery and development
Han, X., & Sun, Y. (2023) · MedComm · doi:10.1002/mco2.290 · Cited by 69
Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells
Otto, C., Schmidt, S., Kastner, C., Denk, S., Kettler, J., Müller, N., Germer, C., Wolf, E., Gallant, P., & Wiegering, A. (2019) · Neoplasia · doi:10.1016/j.neo.2019.10.003 · Cited by 69
MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment
Bartolucci, D., Montemurro, L., Raieli, S., Lampis, S., Pession, A., Hrelia, P., & Tonelli, R. (2022) · Cancers · doi:10.3390/cancers14184421 · Cited by 70
Targeting androgen receptor degradation with PROTACs from bench to bedside
Jia, X., & Han, X. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114112 · Cited by 68
Discovery of a First-in-Class Mitogen-Activated Protein Kinase Kinase 1/2 Degrader
Wei, J., Hu, J., Wang, L., Xie, L., Jin, M. S., Chen, X., Liu, J., & Jin, J. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01528 · Cited by 67
Cullin Ring Ubiquitin Ligases (CRLs) in Cancer: Responses to Ionizing Radiation (IR) Treatment
Fouad, S., Wells, O. S., Hill, M. A., & D’Angiolella, V. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01144 · Cited by 67
A Bioorthogonal Small Molecule Selective Polymeric “Clickase”
Chen, J., Li, K., Bonson, S. E., & Zimmerman, S. C. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c06553 · Cited by 63
DrugnomeAI is an ensemble machine-learning framework for predicting druggability of candidate drug targets
Raies, A. B., Tulodziecka, E., Stainer, J., Middleton, L., Dhindsa, R. S., Hill, P., Engkvist, O., Harper, A. R., Petrovski, S., & Vitsios, D. (2022) · Communications Biology · doi:10.1038/s42003-022-04245-4 · Cited by 65
Application of machine learning models for property prediction to targeted protein degraders
Peteani, G., Huynh, M. T. D., Gerebtzoff, G., & Rodríguez-Pérez, R. (2024) · Nature Communications · doi:10.1038/s41467-024-49979-3 · Cited by 73
Journey of PROTAC: From Bench to Clinical Trial and Beyond
Berkley, K., Zalejski, J., Sharma, N., & Sharma, A. K. (2025) · Biochemistry · doi:10.1021/acs.biochem.4c00577 · Cited by 62
Proteolysis targeting chimeras (PROTACs) for epigenetics research
Vogelmann, A., Robaa, D., Sippl, W., & Jung, M. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.01.010 · Cited by 59
Advances in targeted therapy for tumor with nanocarriers: A review
Cheng, H., Liao, J., Ma, Y., Sarwar, M. T., & Yang, H. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101583 · Cited by 67
Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
Ma, S., Ji, J., Tong, Y., Zhu, Y., Dou, J., Zhang, X., Xu, S., Zhu, T., Xu, X., You, Q., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.022 · Cited by 59
Proteolysis-targeting drug delivery system (ProDDS): integrating targeted protein degradation concepts into formulation design
Chen, Y., Liu, F., Pal, S., & Hu, Q. (2024) · Chemical Society Reviews · doi:10.1039/d4cs00411f · Cited by 59
Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation
Xi, M., Chen, Y., Yang, H., Xu, H., Du, K., Wu, C., Xu, Y., Deng, L., Luo, X., Yu, L., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.036 · Cited by 57
Dual targeting of SREBP2 and ERRα by carnosic acid suppresses RANKL-mediated osteoclastogenesis and prevents ovariectomy-induced bone loss
Zheng, Z., Cheng, H., Zhou, Y., Zhu, S.-T., Thu, P. M., Li, H., Li, P., & Xu, X. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-019-0484-5 · Cited by 57
Recent Advances in PROTAC-Based Antiviral Strategies
Ahmad, H., Zia, B., Husain, H., & Husain, A. (2023) · Vaccines · doi:10.3390/vaccines11020270 · Cited by 57
Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor
Hu, R., Wang, W., Yang, Y.-Y., Hu, X.-T., Wang, Q., Zuo, W., Xu, Y., Feng, Q., & Wang, N. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113922 · Cited by 53
Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells
Mu, X., Bai, L., Xu, Y., Wang, J., & Lu, H. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.11.007 · Cited by 52
Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer
Chen, L., Han, L., Mao, S., Xu, P., Xu, X., Zhao, R., Wu, Z., Zhong, K. L., Yu, G., & Wang, X. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113307 · Cited by 53
SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines
Ehrenhöfer-Wölfer, K., Puchner, T., Schwarz, C., Rippka, J., Blaha-Ostermann, S., Strobl, U., Hörmann, A., Bader, G., Kornigg, S., Zahn, S. K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-48152-x · Cited by 51
MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment
Vicente, A. T. S., & Salvador, J. A. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911068 · Cited by 56
Triazol: A Privileged Scaffold for Proteolysis Targeting Chimeras
Xia, L., Ba, M.-Y., Liu, W., Cheng, W., Hu, C.-P., Zhao, Q., Yao, Y., Sun, M., & Duan, Y. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0159 · Cited by 51
PROTAC technology for the treatment of Alzheimer’s disease: advances and perspectives
Inuzuka, H., Liu, J., Wei, W., & Rezaeian, A.-H. (2022) · Acta Materia Medica · doi:10.15212/amm-2021-0001 · Cited by 52
Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents
Wang, C., Zhang, Y., Shi, L., Yang, S., Chang, J., Zhong, Y., Li, Q., & Xing, D. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2074414 · Cited by 50
Deciphering the mechanism of E3 ubiquitin ligases in plant responses to abiotic and biotic stresses and perspectives on PROTACs for crop resistance
Su, Y., Ngea, G. L. N., Wang, K., Lu, Y., Godana, E. A., Ackah, M., Yang, Q., & Zhang, H. (2024) · Plant Biotechnology Journal · doi:10.1111/pbi.14407 · Cited by 49
Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8
Sun, Z., Deng, B., Yang, Z., Mai, R., Huang, J., Ma, Z., Chen, T., & Chen, J. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114544 · Cited by 46
Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020)
Dockerill, M., Gregson, C. L., & O’Donovan, D. H. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1841167 · Cited by 46
Advances in high‐resolution mass spectrometry applied to pharmaceuticals in 2020: A whole new age of information
Géhin, C., & Holman, S. W. (2021) · Analytical Science Advances · doi:10.1002/ansa.202000149 · Cited by 44
Novel STAT3 Inhibitors Targeting STAT3 Dimerization by Binding to the STAT3 SH2 Domain
Hua, Y., Xing, Y., Shen, Y., Wang, J., Azeem, W., Yang, S., Gade, A., Lellahi, S. M., Oyan, A. M., Ke, X., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.836724 · Cited by 44

Authors: An, S., & Fu, L.
Affiliations: Sun Yat-sen University Cancer Center (CN)
Sun Yat-sen University (CN)
Corresponding author: Fu, Liwu
ORCID: Fu, Liwu
Venue: EBioMedicine
Publisher: Elsevier BV
Published: 2018-10
Volume: 36
Pages: 553-562
ISSN: 2352-3964 (ISSN-L)
DOI: 10.1016/j.ebiom.2018.09.005
PMC: PMC6197674
OpenAlex: W2890850288
Cited by: 363
References: 75
Citations by year: 2026: 36 · 2025: 40 · 2024: 57 · 2023: 37 · 2022: 57 · 2021: 55 · 2020: 46 · 2019: 35
FWCI: 3.43
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: EBioMedicine (publishedVersion, cc-by-nc-nd)
Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders: Natural Science Foundation of Guangdong Province (2016A030312014)
National Key Scientific Instrument and Equipment Development Projects of China (2018ZX09711002-003-011)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Keywords: PROTACs, targeted protein degradation, ubiquitin-proteasome system, target selectivity, drug resistance, tumor xenografts, intracellular protein degradation, targeted therapy
MeSH terms: Animals, Antineoplastic Agents, Humans, Signal Transduction, Biomarkers, Proteasome Endopeptidase Complex, Small Molecule Libraries, Ubiquitination, Drug Discovery, Molecular Targeted Therapy, Proteolysis, Proteasome Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks